Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

89P - Treatment patterns, overall survival (OS), and disease-free survival (DFS) in early stage non-small cell lung cancer (NSCLC) following complete resection

Date

03 Apr 2022

Session

Poster Display session

Presenters

Howard West

Citation

Annals of Oncology (2022) 33 (suppl_2): S71-S78. 10.1016/annonc/annonc857

Authors

H. West1, X. Hu2, T. Burke3, M.S. Walker4, Y. Wang4, A. Samkari3

Author affiliations

  • 1 City of Hope Comprehensive Cancer Center, Duarte/US
  • 2 Merck & Co., Inc., 7033 - Kenilworth/US
  • 3 Merck & Co., Inc., Kenilworth/US
  • 4 ConcertAI, Memphis/US
More

Abstract 89P

Background

To understand adjuvant therapy use and clinical burden in patients (pts) with completely resected stage IB-IIIA NSCLC, this study described adjuvant therapy treatment pattern, OS, and DFS following surgery in the early-stage NSCLC population.

Methods

This retrospective study used data from the ConcertAI Patient360™ database, primarily drawn from United States (US) community oncology practices. Pts with a primary diagnosis of stage IB to IIIA NSCLC were eligible if they had undergone complete resection prior to March 1, 2016. Pts with neoadjuvant therapy or impaired performance were excluded. Adjuvant therapy use was summarized, and OS/DFS using Kaplan-Meier (KM) methods were examined by stage at initial diagnosis. Data cutoff was July 1, 2021.

Results

The study included 441 pts (median age 67 years, 50.3% male), of whom 153 pts had stage IB, 183 had stage II, and 105 had stage IIIA. The proportion of patients receiving adjuvant therapy after complete resection was highest in stage IIIA (50.5%), followed by stage II (42.1%) and stage IB (15.7%). The most common adjuvant regimen was platinum-based therapy with docetaxel or paclitaxel (41.6%). Median OS was 86.5 months for stage IB, 79.4 months for stage II, and 71.7 months for stage IIIA. KM-estimated survival rate at 5 years was 72.6% for stage IB, 64.0% for stage II, and 58.5% for stage IIIA. Median DFS was 57.8 months for stage IB, 36.6 months for stage II, and 34.4 months for stage IIIA. KM-estimated DFS rate at 3 years was 63.6% for stage IB, 51.8% for stage IIB, and 48.7% for stage IIIA.

Conclusions

Although recommended by clinical guidelines, the rate of adjuvant therapy delivery was low in pts with early-stage NSCLC following resection in US oncology practices. Worse outcomes were observed in pts with higher disease stage at diagnosis. Survival rates were higher for patients with stage II and IIIA NSCLC than historical benchmarks.

Legal entity responsible for the study

ConcertAI.

Funding

Merck & Co., Inc.

Disclosure

H. West: Financial Interests, Personal, Other, Consultant: Amgen; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca; Financial Interests, Personal, Other, Consultant: AstraZeneca; Financial Interests, Personal, Other, Consultant: Eli Lilly; Financial Interests, Personal, Speaker’s Bureau: Genentech/Roche; Financial Interests, Personal, Other, Consultant: Genentech/Roche; Financial Interests, Personal, Advisory Board: Merck & Co., Inc; Financial Interests, Personal, Other, Consultant: Merck & Co., Inc; Financial Interests, Personal, Other, Consultant: Mirati; Financial Interests, Personal, Other, Consultant: Pfizer; Financial Interests, Personal, Other, Consultant: Regeneron. X. Hu: Financial Interests, Personal, Full or part-time Employment: MSD, Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc., Kenilworth, NJ, USA. T. Burke: Financial Interests, Personal, Full or part-time Employment: MSD, Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc., Kenilworth, NJ, USA. M.S. Walker: Financial Interests, Personal, Full or part-time Employment: ConcertAI; Financial Interests, Institutional, Funding: Merck & Co., Inc. Y. Wang: Financial Interests, Personal, Full or part-time Employment: ConcertAI; Financial Interests, Institutional, Funding: Merck & Co., Inc. A. Samkari: Financial Interests, Personal, Full or part-time Employment: MSD, Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA ; Financial Interests, Personal, Stocks/Shares: Merck & Co., Inc., Kenilworth, NJ, USA.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.